Merck and Moderna announced positive results from a large late-stage trial of their personalized mRNA cancer vaccine, which significantly reduced the recurrence
Merck and Moderna announced positive results from a large late-stage trial of their personalized mRNA cancer vaccine, which significantly reduced the recurrence of melanoma, the deadliest form of skin cancer.
Madison Muller reports
[▻](https://video.twimg.com/amplify_vi…
Share this article
📚 More from Billy’s World
Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y •
YouTube: @BankingWithBilly